Diary - News
All news ORPHELIA Pharma announces Orphan Drug Designation granted by EMA for temozolomide
ORPHELIA Pharma announces Orphan Drug Designation granted by EMA for temozolomide in the treatment of neuroblastoma
Development of Kimozo®, the first paediatric formulation of temozolomide
Paris and Lyon, September 3rd, 2019 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion for the Orphan Drug Designation of temozolomide in the treatment of neuroblastoma.
